Related references
Note: Only part of the references are listed.High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women
Angela Watt et al.
Infectious Agents and Cancer (2012)
Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes
Johanna Palmroth et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2010)
Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women
Marjo Kaasila et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children
Susan S. Huang et al.
PEDIATRICS (2009)
Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda
Cecily Banura et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s
Matti Lehtinen et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
International Standard reagents for harmonization of HPV serology and DNA assays - an update
Sonia R. Pagliusi et al.
VACCINE (2006)
Human papillomavirus infections with multiple types and risk of cervical neoplasia
Helen Trottier et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses
Ruanne V. Barnabas et al.
PLOS MEDICINE (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses
M Ferguson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
High prevalence of HPV among female students in Finland
E Auvinen et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2005)
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland
P Laukkanen et al.
JOURNAL OF GENERAL VIROLOGY (2003)
Human papillomavirus types in invasive cervical cancer worldwide:: a meta-analysis
GM Clifford et al.
BRITISH JOURNAL OF CANCER (2003)
High incidence of cervical human papillomavirus infection in women during their first sexual relationship
S Collins et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2002)
Concurrent and sequential acquisition of different genital human papillomavirus types
KK Thomas et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Prerequisites for human papillomavirus vaccine trial: results of feasibility studies
J Paavonen et al.
JOURNAL OF CLINICAL VIROLOGY (2000)
Share Paper
